A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects

Preclinical studies demonstrate that pharmacological mobilization and recruitment of endogenous bone marrow stem cells and immunoregulatory cells by a fixed-dose drug combination (MRG-001) improves wound healing, promotes tissue regeneration, and prevents allograft rejection. In this phase I, first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadi, Ali R., Atiee, George, Chapman, Bart, Reynolds, Laurie, Sun, John, Cameron, Andrew M., Wesson, Russell N., Burdick, James F., Sun, Zhaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518600/
https://www.ncbi.nlm.nih.gov/pubmed/37633275
http://dx.doi.org/10.1016/j.xcrm.2023.101169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518600/
https://www.ncbi.nlm.nih.gov/pubmed/37633275
http://dx.doi.org/10.1016/j.xcrm.2023.101169

Ejemplares similares